Seikagaku Grows in Low Double-Digits on Favorable U.S. Reimbursement Status

Seikagaku reported FY 2Q19 revenue of JPY ¥7,906MM (USD $71.4MM), +12.5% vs. 2Q18.

U.S. viscosupplement sales had sizeable volume increases due to qualification for preferential reimbursement status with multiple insurance carriers and well as conversion of competitive accounts
Sales of five injection treatment SUPARTZ FX saw volume...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us